IN8bio

IN8bio Gross Margin

Gross Margin of IN8bio (INAB) as of Nov 11, 2026.

Gross Margin

-

Last updated:

Gross Margin of IN8bio is 2026 - . Gross Margin of IN8bio was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IN8bio Stock analysis

What does IN8bio do? IN8bio Inc is a clinical-stage biopharmaceutical company based in New York City, operating in the Health Care sector within the Biotechnology industry. The company develops novel therapies using allogeneic, autologous, and genetically modified gamma-delta T cells for treating cancers, including solid tumors and hematologic malignancies. With 26 employees, it focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates, currently advancing Phase 1 and Phase 2 clinical trials for glioblastoma and other cancer treatments. IN8bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IN8bio stock

On Eulerpool you can find the complete historical development of Gross Margin IN8bio since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's IN8bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — IN8bio

All Key Metrics — IN8bio